Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors	Neoplasms by Histologic Type, Neoplasms, Germ Cell, Neoplasms, Germ Cell and Embryonal, neoplasm	Active, not recruiting	Phase 2	2026-08-06		NCT01873326

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Mayo Clinic	970
Memorial Sloan Kettering Cancer Center	753
Stanford University	620
University of Chicago	326
University of North Carolina	30
University of Pittsburgh	313
University of Southern California	216
University of Texas Southwestern Medical Center	295

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Mayo Clinic	Rochester	United States	664
Memorial Sloan Kettering Bergen (Follow-up Only)	Montvale	United States	2
Memorial Sloan Kettering Cancer Center	Basking Ridge	United States	12
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Memorial Sloan Kettering Cancer Center @ Suffolk	Commack	United States	14
Memorial Sloan Kettering Monmouth	Middletown	United States	206
Memorial Sloan Kettering Nassau	Uniondale	United States	193
Memorial Sloan Kettering Westchester	Harrison	United States	204
Stanford University Medical Center	Stanford	United States	4
University of Chicago	Chicago	United States	1
University of North Carolina	Chapel Hill	United States	38
University of Pittsburgh Medical Center	Pittsburgh	United States	127
University of Southern California	Los Angeles	United States	110